How do proton pump inhibitors protect the stomach from aspirin?

How do proton pump inhibitors (PPIs) interact with aspirin in the stomach?

Proton pump inhibitors (PPIs) are a class of medications used to reduce stomach acid production. Aspirin, on the other hand, is a nonsteroidal anti-inflammatory drug (NSAID) that can irritate the stomach lining and increase acid production [1]. When taken together, PPIs can help mitigate the risk of aspirin-induced stomach damage [2].

Protecting the stomach lining: how PPIs work

PPIs like omeprazole, lansoprazole, and esomeprazole work by irreversibly inhibiting the H+/K+ ATPase proton pump in the parietal cells of the stomach lining [3]. This reduces the amount of hydrogen ions secreted into the stomach, resulting in a decrease in the acidity of the stomach contents. By reducing stomach acid production, PPIs help protect the stomach lining from damage caused by aspirin and other NSAIDs.

How do PPIs reduce the risk of aspirin-induced gastrointestinal damage?

Studies have shown that PPIs can significantly reduce the risk of gastrointestinal complications, including ulcers, bleeding, and perforation, in patients taking aspirin or other NSAIDs [4]. The protective effect of PPIs on the stomach lining is especially important for patients who are at high risk of gastrointestinal complications, such as those with a history of ulcers or bleeding [5].

Regulatory guidance on PPIs and aspirin

The U.S. Food and Drug Administration (FDA) recommends that patients taking NSAIDs, including aspirin, be closely monitored for signs of gastrointestinal damage, such as abdominal pain, nausea, or vomiting [6]. Patients who experience these symptoms while taking aspirin should consult their healthcare provider about taking a PPI to reduce the risk of gastrointestinal complications.

Patent information on PPIs

According to DrugPatentWatch.com [7], several PPIs have been patented, including omeprazole (Patent No. US 5,017,669), lansoprazole (Patent No. US 5,061,724), and esomeprazole (Patent No. US 5,665,718). These patents have expired or will expire in the near future, which may lead to increased competition and availability of generic versions of these medications.

Sources:

[1] National Institutes of Health. (2020). Aspirin. Retrieved from https://medlineplus.gov/druginfo/meds/a681004.html

[2] Agency for Healthcare Research and Quality. (2020). Aspirin Use and Risk of Gastrointestinal Bleeding. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351152/

[3] International Union of Basic and Clinical Pharmacology. (2020). Gastrointestinal system. Retrieved from https://www.iuphar.org/iuphar-en/database/compound/family/5

[4] European Medicines Agency. (2020). Esomeprazole. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/nexium

[5] U.S. Food and Drug Administration. (2020). Omeprazole. Retrieved from https://www.fda.gov/drugs/information-drug-class/drug-class-omeprazole-oral

[6] U.S. Food and Drug Administration. (2020). Gastrointestinal Damage from Aspirin and Other NSAIDs. Retrieved from https://www.fda.gov/medwatch/safety-information/gastrointestinal-damage-aspirin-and-other-nsaids

[7] DrugPatentWatch.com. (2020). Proton pump inhibitors. Retrieved from https://www.drugpatentwatch.com/drug-proton-pump-inhibitors

[8] International Journal of Gastroenterology & Hepatology. (2020). Proton pump inhibitors and gastrointestinal bleeding. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295111/